SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Policies (Details) (USD $)
|
12 Months Ended | 12 Months Ended | 0 Months Ended | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Jan. 27, 2014
|
Dec. 31, 2013
Pharmacogenomic services
|
Dec. 31, 2012
Pharmacogenomic services
|
Dec. 31, 2013
Diagnostic tools
|
Dec. 31, 2012
Diagnostic tools
|
Dec. 31, 2011
Warrant
|
Dec. 31, 2011
Common Stock
|
Dec. 31, 2011
Accumulated Deficit
|
Dec. 31, 2013
Minimum
|
Dec. 31, 2013
Maximum
|
Dec. 31, 2013
Familion
Minimum
|
Dec. 31, 2013
Familion
Maximum
|
Jan. 27, 2014
Subsequent event
|
||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||||||||||||||||||
Common stock reverse stock split, conversion ratio | 0.0833 | ||||||||||||||||||||
Common stock, par value | $ 0.01 | [1] | $ 0.01 | [1] | $ 0.01 | [1] | |||||||||||||||
Amortization expense, 2014 decrease | $ 400,000 | ||||||||||||||||||||
Finite-lived intangible asset, useful life | 7 years | 8 years | |||||||||||||||||||
Preferred stock revaluation | 0 | 0 | 6,066,000 | 5,800,000 | 300,000 | ||||||||||||||||
Equity awards, contractual term | 10 years | ||||||||||||||||||||
Equity awards, vesting period | 1 year | 3 years | |||||||||||||||||||
Deferred revenue | 1,088,000 | 1,171,000 | 200,000 | 200,000 | 900,000 | 1,000,000 | |||||||||||||||
Other accrued liabilities | 2,037,000 | 3,686,000 | |||||||||||||||||||
Foreign currency translation adjustment, net of tax | (45,000) | 99,000 | 54,000 | ||||||||||||||||||
Foreign currency translation income (loss) | 100,000 | (100,000) | |||||||||||||||||||
Federal grant income, net of consulting fees | 200,000 | ||||||||||||||||||||
Reclassification of other comprehensive income (loss) | $ 0 | $ 1,307,000 | |||||||||||||||||||
Options, warrants and conversion rights, common stock callable and antidilutive (in shares) | 3,785,709 | 2,471,670 | 1,470,689 | ||||||||||||||||||
|